Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học Critical Care giúp cho các bạn có thêm kiến thức về ngành y học đề tài: Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics. | BioMed Central Comparative Hepatology Research Low affinity glucocorticoid binding site ligands as potential anti-fibrogenics Carylyn J Marek 1 Karen Wallace1 2 Elaine Durward1 Matthew Koruth1 Val Leel1 Lucy J Leiper1 and Matthew C Wright1 2 Open Access Address 1Institute of Medical Sciences University of Aberdeen Foresterhill Aberdeen UK and institute of Cellular Medicine Newcastle University Framlington Place Newcastle Upon Tyne UK Email Carylyn J Marek - Karen Wallace - Elaine Durward - Matthew Koruth - Val Leel - Lucy J Leiper - Matthew C Wright - Corresponding author Published II May 2009 Received 7 November 2008 Comparative Hepatology 2009 8 1 doi 1476-5926-8-1 Accepted 1 1 May 2009 This article is available from http content 8 1 1 2009 Marek et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract Background Pregnane X receptor PXR agonists inhibit liver fibrosis. However the rodent PXR activator pregnenolone 16a carbonitrile PCN blocks in vitro hepatic stellate cell-to-myofibroblast trans-differentiation and proliferation in cells from mice with a disrupted PXR gene suggesting there is an additional anti-fibrogenic drug target for PCN. The role of the low affinity glucocorticoid binding site LAGS - which may be identical or associated with the progesterone receptor membrane component 1 PGRMC1 - in mediating this anti-fibrogenic effect has been examined since binding of dexamethasone to the LAGS in liver microsomal membranes has previously been shown to be inhibited by PCN. Results Quiescent rat and human .
